Abstract
The study of the interaction between the host and the neoplastic cell is of fundamental importance in oncology. The topic has been frequently reviewed, so that the present chapter need only review the reviews, highlighting conclusions which are clinically relevant.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Spector BD, Perry GS III, Kersey JH: Genetically determined immunodeficiency diseases and malignancy: Report for the immunodeficiency — Cancer Registry. Clin Immunol Immunopathol, 1978; 11: 12–29.
Melief CJM, Schwartz RS: Immunocompetence and malignancy. In Cancer: A comprehensive treatise. Becker FF (ed). New York, Plenum Press, 1975: 121–60.
Kersey JH, Spector BD, Good RA. Immunodeficiency and cancer. Advances Cancer Res, 1973; 18: 211–30.
Congress of the United States: Review of the public health service’s response to AIDS. A technical memorandum. Office of Technology Assessment, Washington D.C., 1985.
Reed DM: On the pathological changes in Hodgkin’s disease with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rev, 1902; 10: 133–96.
Young RC, Corder MP, Haynes MA, DeVita VT: Delayed hypersensitivity in Hodgkin’s disease. Am J Med, 1972; 52: 63–72.
Eltringham JR, Kaplan HS: Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkin’s disease. Natl Cancer Inst Monograph, 1973; 36: 107–15.
Brown RS, Haynes HA, Foley HT, Goodwin HA, Berard CW, Carbone PP: Hodgkins’ disease. Immunologic clinical and histologic features of 50 untreated patients. Ann Intern Med, 1967; 67: 291–302.
Kelly WD, Good RA, Varco RL, Levitt M: The altered response to skin monografts and to delayed allergens in Hodgkin’s disease. Surg Forum, 1958; 9: 785–89.
Levy R, Kaplan HS: Impaired lymphocyte function in untreated Hodgkin’s disease. N Engl J Med, 1974; 290: 181–86.
Kaplan HS: Hodgkin’s Disease. 2nd edn. Cambridge, Mass, Harvard University Press, 1980.
Fuks Z, Strober S, Kaplan HS: Interaction between serum factors and T lymphocytes in Hodgkin’s disease: use as a diagnostic test. N Engl J Med, 1976; 295: 1273–78.
Posner MR, Reinherz EL, Breard J, Nadler LM, Rosenthal DS, Schlossman SF: Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin’s disease. Cancer, 1978; 48: 1170–76.
De Sousa M, Smithyman A, Tan C: Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for non-binding proteins in the control of lymphoid cell migration. Am J Pathol, 1978; 90: 497–520.
Jones SE, Griffith K, Dombrowski P, Gaines JA: Immunodeficiency in patients with non-Hodgkin’s lymphomas. Blood, 1977; 49: 335–44.
Advani SH, Dinshaw KA, Nair CN, Gopal R, Talwalkar GV, Iyyer YS, Bhatia HM, Desai PB: Immune dysfunction in non-Hodgkin’s lymphoma. Cancer, 1980; 45: 2843–48.
Nedelkova M, Bacalova S, Georgiera B: Infectious complications and host immune defence in acute leukaemia. Eur J Cancer, 1981; 17: 617–22.
Kay NE, Howe RB, Douglas SD: Effect of therapy on T cell subpopulations in patients with chronic lymphocytic leukaemia. Leuk Res, 1982; 6: 345–48.
Eilber FR, Morton DL: Impaired immunological reactivity and recurrence following cancer surgery. Cancer, 1970; 25: 362–67.
Oldham RK, Weese JL, Herberman RB, Perlin E. Mills M, Heims W, Blom J, Green D, Reid J, Bellinger S, Law I, McCoy JK, Dean JH, Cannon GB, Dieu I: Immunological monitoring and immunotherapy of carcinoma of the lung. Int J Cancer, 1976; 18: 739–49.
Mier A, Stein JA, Ben-Efraim S: Immunocompetence, immunosuppression and human breast cancer. Cancer, 1980; 45: 2061–73.
Cobleigh MA, Braun DP, Harris JE: Quantitation of lymphocytes and T cell subsets in patients with disseminated cancer. J Natl Cancer Inst, 1980; 64: 1041–45.
Mandell GL, Fisher RI, Bostick F, Young RC: Ovarian cancer: a solid tumour with evidence of normal cellular immune function but abnormal B cell function. Am J Med, 1979; 66: 621–24.
Krishnan EC, Menon CD, Krishnan L, Jewell WR: Deficiency in maturation process of macrophages in human cancer. J Natl Cancer Inst, 1980; 65: 273–76.
Snyderman R, Meadows L, Holder W, Wells S Jr: Abnormal monocyte chemotaxis in patients with breast cancer: Evidence for a tumour-mediated effect. J Natl Cancer Inst, 1978; 60: 737–40.
Blomgren H, Berg R, Wasserman J, Glas U: Effect of radiotherapy on blood lymphocyte population in mammary carcinoma. Int J Oncol Biol Phys, 1976; 1: 177–88.
Stjernsward J, Jondal M, Vanky F, Wigzell H, Sealy R: Lymphopenia and change in distribution of human B–T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet, 1972; 1: 1152–56.
Slade MS, Simmons RL, Yunis E, Greenberg LJ: Immunodepression after major surgery in normal patients. Surgery, 1975; 78: 363–72.
Yew FH, Johnson RT: Human B and T lymphocytes differ in UV induced repair capacity. Exp Cell Res, 1978; 113: 227–31.
Fauci AS: Glucocortoid effects on circulating human mononuclear cells. J Reticuloendothelia Soc, 1979; 26: 727–38.
Baum M: Effect of administered hormones on the immune reaction. In: Host Defence in Breast Cancer, Stoll BA (ed). London, Heineman, 1975: 130–46.
Heppner GH, Calabresi P: Effect of sequence of administration of methotrexate, leucovorin and 5 fluorouracil on mammary tumour growth and survival in syngeneic C3H mice. Cancer Res, 1977; 37: 4580–83.
Braun DP, Cobleigh MA, Harris JE: The `rebound overshoot’ phenomenon. A consequence of selective cytotoxic drug effect on immunoregulatory suppression mechanisms. Proc Am Soc Clin Oncol, 1980; 21: 373.
Garber M, Andresi D, Pioch Y, Radal M, Serou B Effect of cyclophosphamide and methylprednisolone on in vitro cellular immune response to allogeneic tumour cells. Correlation with in vivo rejection. Transplantation, 1978; 26: 142–49.
Hosea SW, Burch GG, Broun EJ, Berg RA, Frank MM: Impaired immune response of splenectomised patients in polyvalent pneumococcal vaccine. Lancet, 1981; 1: 804–7.
Baumgartner JD, Glauser MP, Burgo-Black AL, Black RD, Pyndiah N, Chiolero R: Severe cytomegalovirus infection in multiply transfused splenectomised trauma patients. Lancet, 1982; ii: 63–65.
Stone HH, Stanley DG, Dejarness HH: Postsplenectomy viral hepatitis. JAMA, 1967; 199: 851–53.
Goffinet DR, Glastein EJ, Merigan TC: Herpes zostervaricella infections and lymphoma. Ann Intern Med, 1972; 76: 235–40.
Monfardini S, Bajetta E, Arnold CA, Kenda R, Bona-donna G: Herpes zoster-varicella infection in malignant lymphomas. Influence of splenectomy and intensive treatment. Eur J Cancer, 1975; 11: 51–57.
Rebout F, Donaldson SS, Kaplan HS: Herpes zoster and varicella infection in children with Hodgkin’s disease. Cancer, 1978; 41: 95–99.
Donaldson SS, Moore MR, Rosenberg SA, Voski KL: Characterization of post splenectomy bacteraemia among patients with and without lymphoma. N Engl J Med, 1972; 287: 69–71.
Schimpff SC, O’Connell M7, Greene WH, Wiernik PH: Infections in 92 splenectomised patients with Hodgkin’s disease. Am J Med, 1975; 59: 695–701.
Weitzman SA, Aisenberg AC, Siber GR, Smith DH: Impaired humoral immunity in treated Hodgkin’s disease. N Engl J Med, 1977; 297: 245–48.
Donaldson SS, Kaplan HS: Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep, 1982; 66: 977–89.
Fuks Z, Stroker S, Bobrove AM, Sasazuki T, McMichael A, Kaplan HS: Long term effects of radiation on T and B lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest, 1976; 58: 803–14.
Fisher RI, DeVita VT, Bostick F, Vanhaelen C, Houser DM, Hubbard SM, Young RC: Persistent immunologic abnormalities in long term survivors of advanced Hodgkin’s disease. Ann Intern Med, 1980; 92: 595–99.
King GW, Grozea PC, Eyre HJ, LoBuglio AF: Neoantigen response in patients successfully treated for lymphoma: A Southwest Oncology Group Study. Ann Intern Med, 1979; 90: 892–95.
Hancock BW, Bruce L, Whitham MD, Dunsmore IR, Ward AM, Richmond J: Immunity in Hodgkin’s disease: status after 5 years remission. Br J Cancer, 1982; 46: 593–600.
Colby TV, Hoppe RT, Warnke RA: Hodgkin’s disease at autopsy: 1972–1977. Cancer, 1981; 47: 1852–62.
Coltman CA Jr, Dixon DO: Malignancies complicating Hodgkin’s disease: A Southwest Oncology Group 10-year follow-up. Cancer Treat Rep, 1982; 66: 1023–33.
Unger PF, Auderc G, Weil M, Jacquillat C: Tumeurs solides après traitement pour maladie de Hodgkin. Nouv Presse med, 1981; 10: 1463–67.
Bodey GP, Bolivar R, Feinstein V: Infectious complications in leukaemic patients. Semin Hematol, 1982; 19: 193–226.
Bodey GP, Buckley M, Sathe YS, Freireich EF: Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med, 1966; 64: 328–40.
Baldwin RW, Embleton MI: Assessment of cell-mediated immunity to human tumour-associated antigens. Int Rev Exp Pathol, 1977; 17: 49–95.
Hellström KE, Hellström I: Lymphocyte mediated cytotoxicity and blocking serum activity to tumour antigens. Adv Immunol, 1974; 18: 209–77.
Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature, 1975; 256: 495–97.
Hellström KE, Hellström I, Braun JP: Human tumour-associated antigens identified by monoclonal antibodies. Springer Semin Immunopathol, 1982; 5: 127–46.
Baldwin RW, Flannery GR, Pelham JM, Dixon Gray J: Immunomodulation by IFN-conjugated monoclonal antibody to human osteogenic sarcoma. Proc Am Soc Clin Oncol, 1982; 23: 1003.
Kahan BD, Pellis NR, LeGrue SJ, Tanaka T: Immunotherapeutic effects of tumour specific transplantation antigens released by 1-butanol. Cancer, 1982; 49: 1163–73.
Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med, 1981; 306: 517–22.
Fidler IJ, Poste G: Macrophage mediated destruction of malignant tumour cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol, 1982; 5: 161–74.
Fidler II, Raz A: The induction of tumoricidal capacities in mouse and rat macrophages by lymphokines. In: Lymphokines, Pick E (ed). New York, Academic Press, 1981: 345.
Russell SW, Gillespie GY, Pace JL: Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their non-specific cytotoxic capacities. Contemp Top Immunobiol, 1980; 10: 143–66.
Eremin O, Coombs RR, Ashby J: Lymphocytes infiltrating human breast cancers lack NK cell activity and show low levels of NK cell activity. Br J Cancer, 1981; 44: 166–76.
Moore M, Vose BM: Extravascular natural cytotoxicity in man: anti-K562 activity of lymph node and tumour infiltrating lymphocytes. Int J Cancer, 1981; 27: 265–72.
Niitsuma M, Golub SH, Edelstein R, Carmack Holmes E: Lymphoid cells infiltrating human pulmonary tumours: effect of intralesional BCG injection. J Natl Cancer Inst, 1981; 67: 997–1004.
Poste, Kirsh R: Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Cancer Res, 1979; 39: 2582–89.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers. Boston/Dordrecht/Lancaster
About this chapter
Cite this chapter
Rankin, E.M., McVie, J.G. (1985). Immunosuppression and oncology. In: Das, P.C., Sibinga, C.T.S., Halie, M.R. (eds) Supportive therapy in haematology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2577-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2577-2_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9617-1
Online ISBN: 978-1-4613-2577-2
eBook Packages: Springer Book Archive